Market Overview

Why This Abeona Therapeutics Analyst Is Turning Bullish After Q3 Print

Share:
Why This Abeona Therapeutics Analyst Is Turning Bullish After Q3 Print

Abeona Therapeutics Inc’s (NASDAQ: ABEO) stock does not reflect the company’s in-house manufacturing capabilities and pipeline, according to Cantor Fitzgerald.

The Abeona Therapeutics Analyst: Kristen Kluska upgraded Abeona Therapeutics from Neutral to Overweight while maintaining the price target at $4.

The Abeona Therapeutics Thesis: The company’s pipeline has three potential pivotal studies, Kristen Kluska said in an upgrade note.

Abeona Therapeutics expects enrollment in the EB-101 study for RDEB to be completed in the first half of 2021, “with top-line data potentially available in late-2021,” the analyst said. 

The company has achieved target enrollment of 18 patients for MPS IIIA but will continue enrollment through the first quarter, she said. For MPS IIIB, Abeona Therapeutics expects to complete target enrollment in the first quarter.

“While we think it is difficult to put a price on in-house manufacturing capabilities, we are now including a $50M pipeline placeholder for this facility,” Kluska said. 

Abeona Therapeutics is undergoing a strategic review and is “more likely to pursue a partnership or sale at this time,” the analyst said. 

ABEO Price Action: Shares of Abeona Therapeutics had risen by 12.85% to $1.30 at the time of publication Wednesday.

Latest Ratings for ABEO

DateFirmActionFromTo
Nov 2020HC Wainwright & Co.MaintainsBuy
Nov 2020Cantor FitzgeraldUpgradesNeutralOverweight
Nov 2020SVB LeerinkMaintainsOutperform

View More Analyst Ratings for ABEO
View the Latest Analyst Ratings

 

Related Articles (ABEO)

View Comments and Join the Discussion!

Posted-In: Cantor Fitzgerald Kristen KluskaAnalyst Color Penny Stocks Upgrades Analyst Ratings Movers Trading Ideas Best of Benzinga

Latest Ratings

StockFirmActionPT
AOUTWedbushUpgrades24.0
MDLZDeutsche BankMaintains66.0
CHDDeutsche BankMaintains92.0
AEODeutsche BankMaintains29.0
BLMNDeutsche BankMaintains26.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com